Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 42, 3957-3963, October 1, 1982]
© 1982 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chou, T.-C.
Right arrow Articles by Philips, F. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chou, T.-C.
Right arrow Articles by Philips, F. S.

Biochemical Effects of 2'-Fluoro-5-methyl-1-ß-D-arabinofuranosyluracil and 2'-Fluoro-5-iodo-1-ß-D-arabinofuranosylcytosine in Mouse Leukemic Cells Sensitive and Resistant to 1-ß-D-Arabinofuranosylcytosine1

Ting-Chao Chou2, Joseph H. Burchenal, Franz A. Schmid, Thomas J. Braun, Tsann-Long Su, Kyoichi A. Watanabe, Jack J. Fox and Frederick S. Philips

Laboratories of Pharmacology [T-C. C., T. J. B., F. S. P.], Applied Therapy [J. H. B.], Experimental Antitumor Testing [F. A. S.], and Organic Chemistry [T-L. S., K. A. W., J. J. F.], Memorial Sloan-Kettering Cancer Center, New York, New York 10021

2'-Fluoro-5-methyl-1-ß-D-arabinofuranosyluracil (FMAU), like 2'-fluoro-5-iodo-1-ß-D-arabinofuranosylcytosine (FIAC), has potent antiviral activity, but unlike FIAC, it also has antileukemic effects. The two agents and 1-ß-D-arabinofuranosylcytosine (ara-C) are compared herein. Concentrations inhibiting thymidine (dThd) incorporation into DNA by 50% are for FMAU, FIAC, and ara-C, respectively, in L1210/0, 32, 353, and 0.2 µM and in L1210/ara-C, 17, >10,000, and 3,900 µM. Other FMAU analogs, 2'-fluoro-5-iodo-1-ß-D-arabinofuranosyluracil and 2'-fluoro-5-ethyl-1-ß-D-arabinofuranosyluracil, inhibit dThd incorporation equally in ara-C-sensitive and -resistant cells; however, their potencies are weaker than that of FMAU. Similar results are obtained when [3H]deoxyadenosine is used as a precursor of incorporation. In L1210/0 cells, incorporation of [2-14C]FMAU radioactivity into DNA is competitively inhibited by dThd and deoxycytidine (dCyd), whereas the incorporation of [2-14C]FIAC radioactivity is competitively inhibited by dCyd but not appreciably by dThd. In L1210/ara-C cells, incorporation of [2-14C]FMAU is competitively inhibited by dThd but not by dCyd. In L1210/0 cells, FMAU has little inhibitory effect on the tritium release from [5-3H]deoxyuridine but markedly inhibits the incorporation of [2-14C]deoxyuridine into DNA. FIAC, by contrast, predominately inhibits the release of tritium from [5-3H]deoxyuridine but has little effect on subsequent incorporation into DNA. These results suggest that (a) FIAC, but not FMAU, is cross-resistant to ara-C; (b) FMAU is particularly effective against L1210/ara-C cells; (c) FIAC behaves metabolically like dCyd, and FMAU like dThd and dCyd; (d) dCyd and dThd may be used as chemotherapeutic modulators; and (e) FIAC predominately inhibits dThd kinase and/or thymidine monophosphate synthetase, whereas FMAU predominately inhibits DNA polymerase and/or nucleotide kinases. Similar conclusions were obtained when P815/0 and P815/ara-C cells were used. The relative potencies of FIAC and FMAU in inhbiting dThd incorporation into DNA in leukemic sublines correlate with cytotoxicity in vitro and chemotherapeutic effects in vivo.

1 This work was supported by National Cancer Institute Grants CA 27569, CA 18856, CA 08748, CA 18601, and CA 09207 and by the Elsa U. Pardee Foundation.

2 To whom requests for reprints should be addressed.

Received 1/28/82. Accepted 6/29/82.




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
T.-C. Chou
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
Pharmacol. Rev., September 1, 2006; 58(3): 621 - 681.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
S.-H. Liu, K. L. Grove, and Y.-C. Cheng
Unique Metabolism of a Novel Antiviral L-Nucleoside Analog, 2'-Fluoro-5-Methyl-beta -L-Arabinofuranosyluracil: a Substrate for Both Thymidine Kinase and Deoxycytidine Kinase
Antimicrob. Agents Chemother., April 1, 1998; 42(4): 833 - 839.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1982 by the American Association for Cancer Research.